How can less exercise yield better blood sugar and decrease risk of heart disease in diabetes patients? A new study has answers.
Follow-on biologics could reduce insulin therapy costs for diabetes patients, but how? This new study reveals.
Edward C. Chao, DO, says collaboration is the answer and offers three simple steps.
New study finds higher percentage of body fat is associated more with abnormal blood glucose in normal and overweight nondiabetic subjects.
The new diabetes tech in question is the expanding pool of continuous glucose monitoring systems. So, what's your CGM IQ?
New research also found that continuous glucose monitoring by type 1 diabetes patients improved overall glucose control and enhanced quality of life.
New diabetes studies find SGLT2i may reduce all-cause mortality; that telemedicine can improve T2DM care; and that broader screening criteria are better.
Primary hyperparathyroidism--asymptomatic but curable. Here are three clinical pearls to help guide diagnosis and management.
The GLP-1 receptor agonist/metformin combination did not support weight loss in this population but did increase pregnancy rates per in vitro embryo transfer.
Empagliflozin shown to significantly reduce liver fat in patients with T2DM, according to a new study.
In a new study, the GLP-1 receptor agonist semaglutide was associated with greater weight loss than placebo -- and liraglutide.
A high-energy breakfast diet may be an effective strategy to improve diabetes control, according to a new study.
Three new diabetic technologies have been approved by the FDA. What are they? Scroll through our slideshow to find out.
A patch that can detect early symptoms of hypoglycemia is one of three studies discussed in this month's endocrinology news roundup.
From degludec to dulaglutide, we’ve come a long way from the years when there was only one option to treat type 2 diabetes. Here's a look at metformin's place in this history.